Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $34.00 target price on the stock.
Checkpoint Therapeutics Stock Performance
NASDAQ:CKPT opened at $2.67 on Tuesday. The company has a market capitalization of $95.29 million, a PE ratio of -0.96 and a beta of 1.25. The company has a 50 day simple moving average of $1.99 and a two-hundred day simple moving average of $1.93. Checkpoint Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $3.62.
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) last released its earnings results on Friday, May 10th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.04. Research analysts predict that Checkpoint Therapeutics will post -1.24 EPS for the current year.
Insiders Place Their Bets
Hedge Funds Weigh In On Checkpoint Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Armistice Capital LLC lifted its holdings in shares of Checkpoint Therapeutics by 17.5% in the 4th quarter. Armistice Capital LLC now owns 2,426,000 shares of the company’s stock worth $5,556,000 after purchasing an additional 362,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Checkpoint Therapeutics by 67.4% in the 1st quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock worth $1,882,000 after purchasing an additional 369,586 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Checkpoint Therapeutics by 232.3% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock worth $374,000 after purchasing an additional 114,200 shares in the last quarter. Choreo LLC lifted its holdings in shares of Checkpoint Therapeutics by 200.9% in the 1st quarter. Choreo LLC now owns 57,922 shares of the company’s stock worth $119,000 after purchasing an additional 38,672 shares in the last quarter. Finally, 180 Wealth Advisors LLC bought a new position in shares of Checkpoint Therapeutics in the 2nd quarter worth $96,000. 22.00% of the stock is currently owned by institutional investors.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
See Also
- Five stocks we like better than Checkpoint Therapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- Real Estate Stock Signals a Boom in Manufacturing Activity
- Are Penny Stocks a Good Fit for Your Portfolio?
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.